Notice on the 2025 Edition of the Chinese Pharmacopoeia Standard Interpretation Training Class (Guangzhou)
Release time:
2025-04-03
To all relevant units:
The 2025 edition of the Chinese Pharmacopoeia has been promulgated and is about to be implemented. In accordance with the relevant requirements of the National Medical Products Administration on the implementation of the new edition of the pharmacopoeia, in order to ensure that the new edition of the pharmacopoeia is "understood, implemented, and supervised effectively", to conduct relevant policy interpretation and training on the content of standard revisions and amendments, and to contribute to the smooth implementation of the new edition of the pharmacopoeia, the National Pharmacopoeia Commission will hold the "2025 Edition of the Chinese Pharmacopoeia Standard Interpretation Training Class (Guangzhou)" in Guangzhou from May 14 to 16, 2025. This training session will invite relevant leaders from the Drug Registration Department of the National Medical Products Administration, relevant leaders and heads of relevant departments of the National Pharmacopoeia Commission, pharmacopoeia members and relevant experts who participated in the compilation of the new edition of the pharmacopoeia, to conduct in-depth interpretation of the relevant policies, regulations, and standard revisions and amendments related to the implementation of the 2025 edition of the pharmacopoeia, helping the industry to correctly understand and master the changes in the standards of the new edition of the pharmacopoeia, and ensuring the accurate implementation of the new edition of the pharmacopoeia. The relevant matters are notified as follows:
I. Training Time
May 13, 2025, 10:00-18:00, or registration on the 14th from 7:30-8:30, training from May 14-16, 2.5 days of training.
II. Training Location
Training Location: Zhujiang Hotel
Address: No. 2, Siyouyi Road, Yuexiu District, Guangzhou
III. Training Content
For specific training content, please see the attachment.
IV. Training Participants
(1) Relevant management and technical personnel from drug supervision, R&D, and testing institutions and research institutes;
(2) Management and technical personnel responsible for registration applications, quality control, and quality testing in units producing, operating, and using drugs, pharmaceutical excipients, and drug packaging materials.
(3) Relevant technical personnel from foreign pharmaceutical manufacturing enterprises and registration agencies.
V. Other Matters
(1) Training Organization
This training is hosted by the National Pharmacopoeia Commission, co-organized by Guangdong Provincial Drug Inspection Institute and Guangzhou Municipal Drug Inspection Institute.
(2) Registration Method
Please Sign In to the National Pharmacopoeia Commission website
https://www.chp.org.cn/ ,【Public Services】-【Training Registration System】, select the corresponding training class, Sign In/register, and register on-site. Training will be closed once full.
(3) Training Fee
Training fee: 2960 yuan/person (including tuition, venue fee, materials fee, and lunch during the training period).
Please complete the payment as soon as possible after registration. You can pay online directly (scan the QR code in the registration system to pay), or you can remit the payment in advance to the designated account.
Invoices will be sent to your email within 7 working days after the training.
Remittance Information:
Account Name: National Pharmacopoeia Commission
Bank: Industrial Bank Beijing Gymnasium Road Branch
Account Number: 0200008109089270084
Please add the following remarks when remitting: Guangzhou + participating unit, name
(4) After the training, a certificate of completion will be issued by the National Pharmacopoeia Commission.
(5) Transportation and accommodation expenses are at your own expense.
(6) Contact Information
Contact: Li Xiaolei, Qiao Xinru
Tel: 010-67079571, 13810650994
010-67079525, 13522028024
Email: peixun@chp.org.cn
Address: Building 11, Fahua Nanli, Dongcheng District, Beijing
Post Code: 100061
National Pharmacopoeia Commission
April 1, 2025
Latest News